Featured Research

from universities, journals, and other organizations

Rogue gene hijacks stem cells to jumpstart human cancer

Date:
November 10, 2010
Source:
Queen Mary, University of London
Summary:
A gene thought to be responsible for initiating human cancer has been identified by researchers in the UK. The study paves the way for developing early cancer diagnostic tests, and finding new treatments that prevent or stop the spread of cancer cells at an early stage.

A gene thought to be responsible for initiating human cancer has been identified by researchers at Barts and The London School of Medicine and Dentistry. The study -- published online Nov. 9 in the journal Cancer Research -- paves the way for developing early cancer diagnostic tests, and finding new treatments that prevent or stop the spread of cancer cells at an early stage.

Led by Dr Muy-Tek Teh of the Institute of Dentistry at Barts and The London School of Medicine and Dentistry, researchers have shown that a gene called FOXM1 exploits the inherent self-renewal property of stem cells causing excessive cell proliferation. Using adult human stem cells isolated from mouth tissues, the team demonstrated that normal stem cells engineered in the lab to express abnormal levels of FOXM1 gene, triggered excessive cell growth within a 3D tissue culture model system set up to mimic human tissue regeneration in the laboratory. The 3D tissue culture system allows scientists to perform research on manipulated human cells without provoking ethical issues associated with human or animal subjects.

Stem cells expressing normal levels of the FOXM1 gene did not cause excessive cell growth. The abnormal growth triggered by FOXM1 resulted in a condition called hyperplasia -- an early hallmark of pre-cancer. This is thought to represent the very first step of a series of abnormal molecular events leading to cancer formation.

Dr Teh said: "Now we know that FOXM1 plays a key role in cancer initiation we aim to translate our basic findings into clinically useful molecular diagnostic tests to detect cancer growth at early stages. Furthermore, understanding the origin of cancer initiation may unveil new research opportunities for finding effective anti-tumour drugs that stop or prevent cancer at its earliest incipient stage."

The study was co-funded by the Wellcome Trust VIP award, Medical Research Council PhD studentship, the Institute of Dentistry Barts and The London School of Medicine and Dentistry, Queen Mary, University of London and the Norwegian Research Council.


Story Source:

The above story is based on materials provided by Queen Mary, University of London. Note: Materials may be edited for content and length.


Journal Reference:

  1. Emilios Gemenetzidis, Daniela Elena-Costea, Eric K. Parkinson, Ahmad Waseem, Hong Wan, and Muy-Teck Teh. Induction of Human Epithelial Stem/Progenitor Expansion by FOXM1. Cancer Research, 2010; DOI: 10.1158/0008-5472.CAN-10-2173

Cite This Page:

Queen Mary, University of London. "Rogue gene hijacks stem cells to jumpstart human cancer." ScienceDaily. ScienceDaily, 10 November 2010. <www.sciencedaily.com/releases/2010/11/101109133141.htm>.
Queen Mary, University of London. (2010, November 10). Rogue gene hijacks stem cells to jumpstart human cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/11/101109133141.htm
Queen Mary, University of London. "Rogue gene hijacks stem cells to jumpstart human cancer." ScienceDaily. www.sciencedaily.com/releases/2010/11/101109133141.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins